Quotables
"That the automobile has practically reached the limit of its development is suggested by the fact that during the past year no improvements of a radical nature have been introduced."
Scientific American ; Jan. 2 edition, 1909
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7431926 | Tumor supressor gene p33ING2 The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods ... | 10/07/2008 |
| 7422739 | Anti-CD20 antibodies Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders. ... | 09/09/2008 |
| 7417124 | Antibodies specific for phosphorylation sites and screening methods using the same antibodies Polyclonal antibody specific for a phosphorylated linker region in Smad2 and/or Smad3. ... | 08/26/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7374886 | Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a m... | 05/20/2008 |
| 7371827 | Antibodies against the PRO1126 polypeptide The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 05/13/2008 |
| 7355013 | PRO6017 antibodies The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 04/08/2008 |
| 7348414 | Antibodies against the PRO1154 polypeptide The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 03/25/2008 |
| 7342104 | Antibodies against the PRO4320 polypeptide The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 03/11/2008 |
| 7326415 | Antibodies to non-functional P2Xreceptor The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between functional and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies fo... | 02/05/2008 |
| 7314920 | Antibodies against the PRO4340 polypeptide The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 01/01/2008 |
| 7312309 | PRO6017 polypeptides The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 12/25/2007 |
| 7306926 | Method for detecting carcinomas in a solubilized cervical body sample The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly direct... | 12/11/2007 |
| 7304145 | PRO19646 antibodies The present invention is directed to a novel polypeptides having sequence similarity to to a receptor with an immunoglobulin-like domain and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucle... | 12/04/2007 |
| 7294702 | Secreted and transmembrane polypeptides and nucleic acids encoding the same The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 11/13/2007 |
| 7282346 | Methods for cancer prognosis and diagnosis The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a variety of immunohistochemical and genetic markers associated with poor cancer prognosis, and in particular those mark... | 10/16/2007 |
| 7276237 | Human Mob-5 (IL-24) receptors and uses thereof The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also provides methods of inhibiting the Mob-5 receptor as well as methods of... | 10/02/2007 |
| 7273926 | Antibody to PRO1779 polypeptides The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 09/25/2007 |
| 7232887 | Melanoma antigens and their use in diagnostic and therapeutic methods The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, asses... | 06/19/2007 |
| 7230086 | Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices The invention is a method of identifying the presence of a disease state in a mammal which is associated with degradation of connective tissue in the mammal which contains the protein known as YKL-40. The method is a competitive immunoassay for YKL-40. It can be use... | 06/12/2007 |
| 7226750 | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof The present invention is directed to cell surface antigenes found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable ... | 06/05/2007 |
| 7220841 | Antibody to PRO1557 polypeptide encoded by a nucleic acid highly expressed in esophageal and kidney tumors The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 05/22/2007 |
| 7211257 | Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody The present invention is directed to compositions and methods to modulate inflammatory and immune responses in a subject, which includes immune activation and inhibiting inflammatory responses, by modulating the regeneration and tolerance factor (RTF). ... | 05/01/2007 |
| 7198899 | Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents bas... | 04/03/2007 |
| 7138496 | Human monoclonal antibodies against human CXCR4 Compositions are provided that comprise antibody against membrane proteins such as chemokine receptors. In particular, monoclonal human antibodies against human CXCR4 are provided that are capable of inhibiting HIV infection and chemotaxis in human breast cancer cel... | 11/21/2006 |
| 7129330 | Multivalent antibody constructs The present invention relates to multivalent Fvantibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fv | 10/31/2006 |
| 7125681 | Methods for detection of disease-associated antibodies in urine The present invention provides methods and diagnostic kits for the detection of disease-specific antibodies in urine containing sample. The present invention is also directed toward methods for determining that a patient suffers from a disorder characterized by aber... | 10/24/2006 |
| 7118912 | Methods and compositions for categorizing patients The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detec... | 10/10/2006 |
| 7109304 | Humanized anti-CD19 antibodies The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and d... | 09/19/2006 |
| 7105149 | Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein. Provided too, are the IRTA proteins encoded by the isolated nucleic acid molecules, IRTA1, I... | 09/12/2006 |
| 7084255 | PRO1278 polypeptides The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 08/01/2006 |
| 7078491 | Selective binding agents of telomerase The present invention relates to novel selective binding agents including polyclonal and monoclonal antibodies that recognize and bind to the catalytic subunit of human telomerase (hTERT). The invention also relates to the production, diagnostic use, and therapeutic... | 07/18/2006 |
| 7064188 | Monoclonal antibodies which identify the glycoprotein carrying the CA125 epitope Hybridomally produced monoclonal antibodies specifically immunoreactive with the glycoprotein carrying the CA 125 epitope. Monoclonal antibodies recognize both high and low molecular weight subunits of the antigen, and identify the antigen in the cytoplasm and the e... | 06/20/2006 |
| 7060272 | Death domain containing receptor-4 agonist antibodies and methods The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptid... | 06/13/2006 |
| 6998108 | Antibodies to p30 polypeptides and methods making and using same A novel ligand (p30) for herpes virus entry mediator, HVEM, is provided. p30 is useful for modulating immune responses and in inhibiting infection by herpes virus. Methods for treating subjects with lymphoid cell disorders or those having or suspected of having a he... | 02/14/2006 |
| 6991776 | Intracorporeal medicaments for high energy phototherapeutic treatment of disease New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xan... | 01/31/2006 |
| RE38916 | APC Antibodies A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC i... | 12/06/2005 |
| 6965017 | Melanoma antigens and their use in diagnostic and therapeutic methods The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, asses... | 11/15/2005 |
| 6939670 | Cell-based detection and differentiation of lung cancer The present invention provides a method for detecting and differentiating disease states with high sensitivity and specificity. The method allows for a determination of whether a cell-based sample contains abnormal cells and, for certain diseases, is capable of dete... | 09/06/2005 |
| 6924361 | Phosphopeptide-specific antibodies that are activity specific; methods of production and antibody uses This invention relates to growth regulatory proteins expressed in various disease states, especially receptor tyrosine kinases and similar growth factor receptors. Prior to the Applicants invention, it was not clear that specific antibodies could be generated that r... | 08/02/2005 |
